HIF1A and esophageal cancer: Artesunate can promote the degradation of hexokinase 1 (HK1) by targeting it, while simultaneously downregulating the levels of HIF1α and PKM2, thereby inhibiting aerobic glycolysis in esophageal cancer progression.